LSLucie Sedlackova

Lucie Sedlackova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucie Sedlackova has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De novo missense variants in KCNJ4 cause neurodevelopmental disorder with or without seizures

    by Lucie Sedláčková, Katalin Štěrbová, Jana Zárubová, Markéta Havlovicová, Alica Baxová, Joseph D. Farris, Eva S. Kahn, Brendan C. Lanpher, Eric W. Klee, Lucie Rhinan, et al.

  • Open Access

    Novel Variants in KMT2C Further Support a Neurodevelopmental Disorder Distinct From Kleefstra and Kabuki Syndromes

    by Lucie Sedláčková, Dana Šafka Brožková, Markéta Havlovicová, Petra Laššuthová

    Background: Heterozygous loss‐of‐function variants in the KMT2C gene were only recently recognized as a cause of neurodevelopmental disorder distinct from Kleefstra and Kabuki 1 syndromes. KMT2C ‐related neurodevelopmental disorder is characterized by developmental delay, intellectual disability, behavioral and psychiatric problems, seizures, craniofacial dysmorphism, and other comorbidities. Here we describe detailed phenotypes of three additional patients with novel variants in the KMT2C gene. Methods and Results: Using exome sequencing, we found two heterozygous variants c.3212G>A, p.(Trp1071*) and c.13204_13205delinsA, p.(Cys4402Ilefs*11) leading to premature stop codon and one heterozygous missense variant c.6517C>T, p.(Pro2173Ser) in the KMT2C gene (NM_170606.3) in patients with unrecognized neurodevelopmental disorder. Our patients suffer from developmental delay, speech delay, autism spectrum disorder, cognitive impairment, seizures, and/or craniofacial dysmorphism. Conclusion: After detailed phenotype analysis and by comparison with previous reports, we found that our patients have very similar phenotypes as described before and thus further extend the list of KMT2C causal variants. Therefore, we believe that they fit into these previously described phenotypes of KMT2C ‐related Kleefstra syndrome 2 as well.

  • Open Access

    A 5‐year‐old boy with super‐refractory status epilepticus and RANBP2 variant warranting life‐saving hemispherotomy

    by Barbora Straka, Miroslav Koblížek, Barbora Splítková, Radka Valkovičová, Lenka Krsková, Markéta Kalinová, Markéta Vlčková, Josef Zámečník, Petra Laššuthová, Lucie Sedláčková, et al.

    Focal cortical dysplasia (FCD) represents the most common cause of drug‐resistant epilepsy in adult and pediatric surgical series. However, genetic factors contributing to severe phenotypes of FCD remain unknown. We present a patient with an exceptionally rapid development of drug‐resistant epilepsy evolving in super‐refractory status epilepticus. We performed multiple clinical (serial EEG, MRI), biochemical (metabolic and immunological screening), genetic (WES from blood‐ and brain‐derived DNA), and histopathological investigations. The patient presented 1 month after an uncomplicated varicella infection. MRI was negative, as well as other biochemical and immunological examinations. Whole‐exome sequencing of blood‐derived DNA detected a heterozygous paternally inherited variant NM_006267.4(RANBP2):c.5233A>G p.(Ile1745Val) (Chr2[GRCh37]:g.109382228A>G), a gene associated with a susceptibility to infection‐induced acute necrotizing encephalopathy. No combination of anti‐seizure medication led to a sustained seizure freedom and the patient warranted induction of propofol anesthesia with high‐dose intravenous midazolam and continuous respiratory support that however failed to abort seizure activity. Brain biopsy revealed FCD type IIa; this finding led to the indication of an emergency right‐sided hemispherotomy that rendered the patient temporarily seizure‐free. Postsurgically, he remains on antiseizure medication and experiences rare nondisabling seizures. This report highlights a uniquely severe clinical course of FCD putatively modified by the RANBP2 variant.Plain Language Summary: We report a case summary of a patient who came to our attention for epilepsy that could not be controlled with medication. His clinical course progressed rapidly to life‐threatening status epilepticus with other unusual neurological findings. Therefore, we decided to surgically remove a piece of brain tissue in order to clarify the diagnosis that showed features of a structural brain abnormality associated with severe epilepsy, the focal cortical dysplasia. Later, a genetic variant in a gene associated with another condition, was found, and we hypothesize that this genetic variant could have contributed to this severe clinical course of our patient.


  • Open Access

    Yield of exome sequencing in patients with developmental and epileptic encephalopathies and inconclusive targeted gene panel

    by Lucie Sedlackova, Katalin Sterbova, Marketa Vlckova, Pavel Seeman, Jana Zarubova, Petr Marusic, Pavel Krsek, Hana Krijtova, Alena Musilova, Petra Lassuthova


  • Severe neurodevelopmental disorder with intractable seizures due to a novel SLC1A4 homozygous variant

    by Lucie Sedláčková, Petra Laššuthová, Katalin Štěrbová, Markéta Vlčková, Martin Kudr, Irena Buksakowska, David Staněk, Pavel Seeman


  • A novel variant in YWHAG further supports phenotype of developmental and epileptic encephalopathy

    by Lucie Sedláčková, Katalin Štěrbová, Markéta Vlčková, Alice Maulisová, Petra Laššuthová


  • UBTF Mutation Causes Complex Phenotype of Neurodegeneration and Severe Epilepsy in Childhood

    by Petra Laššuthová, Katalin Štěrbová, Jana Haberlová, Emílie Vyhnálková, Jana Neupauerová, David Staněk, Marie Šedivá, Pavel Kršek, Pavel Seeman, Lucie Sedláčková

    Introduction Neurodegenerative diseases of childhood present with progressive decline in cognitive, social, and motor function and are frequently associated with seizures in different stages of the disease. Here we report a patient with severe progressive neurodegeneration with drug-resistant epilepsy of unknown etiology from the age of 2 years. Methods and Results Using whole exome sequencing, we found heterozygous missense de novo variant c.628G > A (p.Glu210Lys) in the UBTF gene. This variant was recently described as de novo in 11 patients with similar neurodegeneration characterized by developmental decline initially confined to motor development followed by language regression, appearance of an extrapyramidal movement disorder, and leading to severe intellectual disability. In 3 of the 11 patients described so far, seizures were also present. Conclusions Our report expands the complex phenotype of neurodegeneration associated with the c.628G > A variant in the UBTF gene and helps to clarify the relation between this one single recurrent pathogenic variant described in this gene to date and its phenotype. The UBTF gene should be considered a novel candidate gene in neurodegeneration with or without epilepsy.


  • Open Access

    Ecologische thematiek in hedendaagse fi ctie: Uitdagingen van milieufi losofi e, ecokritiek en animal studies voor de Nederlandstalige literatuur/ Ecology in the Contemporary Fiction: The Challenges of Environmental Philosophy, Ecocriticism and Animal Studies for the Study of Dutch and Flemish Literature

    by Lucie Sedláčková

    This article is based on the belief that in every historical period, there is a certain part of the literary production that reflects the recent events or tendencies in the contemporary society. Using my dissertation, in which I did research on the representations of the globalisation in recent Dutch and Flemish fiction, as an example of which issues were or were not represented in a number of selected Dutch-written novels, I point out that ecology, which turned to be a non-issue in my corpus, deserves new attention at this moment. My article suggests some attitudes that can help to interpret the ecological issues and the tightly connected subject of animal rights. The new challenges for the literary studies are first of all presented by the ecocriticism and the (critical) animal studies

  • Heat shock protein gene expression profile may differentiate between rheumatoid arthritis, osteoarthritis, and healthy controls

    by L Sedlackova, A Sosna, P Vavrincova, J Frýdl, V Guerriero, DA Raynes, I Hromadnikova

    Objective: Heat shock proteins (Hsps) have been repeatedly implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this work was to study Hsp mRNA and protein levels to determine whether they can be used to differentiate between RA, osteoarthritis (OA), and healthy controls. Methods: Hsp27, Hsp60, Hsp70, Hsp90α, and HspBP1 mRNA expression was analysed using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 24 RA, 11 OA, and 21 healthy controls. Hsp70 and HspBP1 protein levels were measured in serum using an enzyme-linked immunosorbent assay (ELISA). Results: Hsp gene expression profiles differ significantly between inflammatory (RA) and non-inflammatory (OA) joint diseases, showing significantly increased Hsp27 and Hsp90α mRNA levels in RA synovial tissues. Up-regulated Hsp60 and Hsp90α together with down-regulated Hsp70 and elevated HspBP1/Hsp70 mRNA ratios can be used to differentiate between RA patients and healthy individuals through analysis of peripheral blood samples. Despite increased HspBP1 levels in RA sera, Hsp70 levels and the HspBP1/Hsp70 protein ratio remained identical in the RA patients and healthy individuals, which may contribute to the inhibition of Hsp70 anti-apoptotic activity. Conclusion: Hsp gene expression analysis can be implemented as a new diagnostic approach to facilitate differentiation between RA, OA, and healthy controls.


  • Heat-shock protein expression in leukemia

    by Lucie Sedlackova, Martin Spacek, Ernst Holler, Zuzana Imryskova, Ilona Hromadnikova

    Heat-shock proteins (Hsps) are thought to play a role in the development of cancer and to modulate tumor response to cytotoxic therapy. In this study, Hsp27, Hsp60, Hsp90α, and HspBP1 gene expression was investigated in human leukemia cell lines as well as in leukemia cells derived from patients with the onset of the disease. Hsp70 membrane expression and expression of Hsp27, Hsp60, Hsp70, Hsp90α, and HspBP1 genes were also tested in samples from leukemia patients. Relative Hsps gene expression was examined in human leukemia cell lines and also in patients, using real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR). Hsp70 cell surface expression was studied in patients with leukemia onset using flow cytometry. All tested cell lines showed significantly increased expression of Hsp60, Hsp90α, and HspBP1 genes compared with a cohort of healthy controls; additionally there was increased Hsp27 expression except for Jurkat and CCRF cells. Significantly higher gene expression of Hsp27, Hsp60, Hsp90α, and HspBP1 was observed in the peripheral blood of patients compared with bone marrow and healthy control samples, while Hsp70 expression was without any significant difference among cohorts. Hsp70 cell surface expression was found on defrosted and cultured leukemia cells but not on unprocessed biological samples from patients. Leukemia cells showed a heterogeneous pattern of Hsp gene expression among leukemia cell lines as well as in peripheral blood and bone marrow of patients.